The first edition of the clinical practice guidelines for liver cirrhosis was published in 2010,
and the second edition was published in 2015 by the Japanese Society of Gastroenterology …

Rifaximin is an oral nonsystemic antibiotic with minimal gastrointestinal absorption and
broad‐spectrum antibacterial activity covering both gram‐positive and gram‐negative …

The natural history of cirrhosis is characterised by an asymptomatic compensated phase
followed by a decompensated phase, marked by the development of overt clinical signs, the …

Hepatic encephalopathy (HE) is a serious complication of cirrhosis that causes
neuropsychiatric problems, such as cognitive dysfunction and movement disorders. The link …

Clin Mol Hepatol Volume_26 Number_2 April 2020 https://doi. org/10.3350/cmh. 2019.0010
n clinical practice. Therefore, these revised guidelines for the treatment of varices and HE …

A consolidated overview of evidence for the effectiveness and safety/tolerability of hepatic
encephalopathy (HE) treatment over the long term is currently lacking. We identified and …

Patients with cirrhosis are susceptible to develop infections because of immune dysfunction,
changes in microbiome and increase in bacterial translocation from the gut to systemic …

Patients with decompensated cirrhosis are currently managed through targeted strategies
aimed at preventing or treating specific complications. In contrast, a disease-modifying agent …

Background Minimal hepatic encephalopathy (MHE) is an early stage in the pathogenesis of
hepatic encephalopathy. Intestinal microbiota is involved in the pathogenesis of hepatic …

Abstract Background & Aims Alcoholic hepatitis (AH) is associated with a high incidence of
infection and mortality. Rifaximin reduces bacterial overgrowth and translocation. We aimed …